Last reviewed · How we verify
Norprolac — Competitive Intelligence Brief
phase 2
Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Dopamine receptor
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Norprolac (Norprolac) — Ferring Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Norprolac TARGET | Norprolac | Ferring Pharmaceuticals | phase 2 | Adrenergic receptor alpha-1, Adrenergic receptor alpha-2, Dopamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Norprolac — Competitive Intelligence Brief. https://druglandscape.com/ci/norprolac. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing